6 news items
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
NUVB
14 May 24
, offset by a $0.7 million increase in personnel-related costs driven by stock-based compensation and other benefits
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
NUVB
10 Apr 24
organization, potential therapeutic benefit of Nuvation Bio's product candidates, development of our pipeline, and the sufficiency of Nuvation Bio's current
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
NUVB
28 Mar 24
organization and the potential therapeutic benefit of Nuvation Bio's product candidates. These statements are based on various assumptions, whether
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
NUVB
25 Mar 24
of the Acquisition, expected timing of establishing a commercial organization, potential therapeutic benefit of Nuvation Bio and AnHeart's product candidates
Biotech's Role in Addressing the Pancreatic Cancer Emergency
ACRS
IBRX
NUVB
14 Mar 24
and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients
mcbwn78484cj8nq ptb4f7b5zxlg9go0cgtw
NUVB
29 Feb 24
-looking statements include, but are not limited to, statements regarding the potential therapeutic benefit of Nuvation Bio's product candidates
- Prev
- 1
- Next